AI Proteins Secures $41.5M Series A Financing to Advance De Novo Miniprotein Therapeutics

November 19, Boston, AI Proteins is aAI Proteins, Inc., a biotechnology company pioneering a new class of AI-built drugs from scratch, announced the completion of a $41.5 million Series A financing round. The round was led by Mission BioCapital and Santé Ventures, with participation from existing investors including Lightchain Capital, Cobro Ventures, and others.Also participated in it. (New Frontier! AI Proteins Secures $18.2 Million in Seed Funding to Develop Microprotein Therapies）

This financing will accelerate AI Proteins' mission to unlock from scratchMicro EggWhite Matter (miniproteins) The next-generation transformative new drug constructed. Generative artificial intelligence, synthetic biologyThe integration with robotics technology powers the company's discovery platform and makes the creation of this novel therapy possible. AI Proteins' modularityMicroAI Proteins are created entirely from first principles, free from the constraints of evolution or human bias, to achieve full control over function, stability, solution behavior, and pharmacology. They can be tailored to complex and diverse mechanisms of action, including targeted delivery or multi-specific drugs.

AI ProteinsFounder and CEO Chris Bahl, Ph.D., stated:"Natural proteins have evolved under selective pressures in their environments. They did not evolve for modern medicine. Antibodies have transformed patient care but are limited by their natural origins. The next wave of biologics will do what natural proteins cannot, as they are built from the ground up. We start our design process with a Target Product Profile and work backward to create the exact molecule needed. This level of control and precision was previously impossible. By industrializing the design-build-test cycle, we generate and optimize small protein candidates with speed and scale, collecting massive datasets to refine our models and accelerate our progress."

AI Proteins Demonstrates the Power and Scalability of Its Platform Through Internal Projects and Partnerships. In December 2024, the company announced a research collaboration and option agreement with Bristol-Myers Squibb, valued at up to $400 million. Internally, AI Proteins has generated molecules targeting over 150 targets, with multiple projects demonstrating in vivo proof-of-concept. Beyond human therapeutics, AI Proteins' platform is opening new frontiers in diagnostics, agriculture, and reagent applications, where de novo miniproteins can replace or outperform naturally derived proteins.

Steve Tregay, Ph.D., Managing General Partner of Mission BioCapital, stated:“AI Proteins"Transforming the historical manual science into a repeatable and scalable process capable of generating molecules in the therapeutic field. We see AI Proteins as a foundational company aimed at unlocking an entirely new class of proteins."

Unlike traditional biotechnology platforms that are often downgraded after acquiring successful assets, AI Proteins is focused on driving long-term innovation and shaping the future of de novo design. The company is safeguarding and expanding its core platform by adopting an LLC hub-and-spoke business model. This approach ensures the continuous development of the discovery engine while enabling investors and partners to extract value from each new asset by spinning off individual projects into dedicated subsidiaries.

Omar Khalil, Managing Director of Santé Ventures, stated:"AI Proteins has built a platform that is not only scientifically differentiated but also operationally designed for scale. It is a platform that can power a new generation of therapies and advancements across diverse fields."

Follow the official account below to see the world!